Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (Epithelial Necrolysis)

  • Jean-Claude Roujeau


Incidence of epithelial necrolysis (EN) is approximately two cases/million inhabitants/year. Adult women are overrepresented, and in childhood the sex ratio is more equal. The diagnosis of EN is often clinically apparent on examination of the skin and mucous membranes. Skin pathology helps differentiation from other blistering diseases. A prognosis score (SCORTEN) estimates the risk of death and the emergency of transfer to specialized wards (intensive care unit (ICU), Burn Units). A few “high-risk” medications cause close to 50% of cases (allopurinol, sulfamethoxazole, lamotrigine, carbamazepine, phenytoin, phenobarbital, oxicam class or Cox2 inhibitor class NSAIDs). Immediate withdrawal of suspect drug(s) and symptomatic therapeutic measures gives similar outcomes to those used in extensive burns. Cyclosporine A and etanercept likely decrease mortality.


Epithelial necrolysis (EN) Drug-induced cytotoxicity Idiopathic cases High mortality Sequelae Symptomatic care Cyclosporine A 



Body surface area


Confidence interval


Epithelial necrolysis


Intensive care unit


Intravenous immunoglobulins


Protocole National de Diagnostic et de Soins


Post-traumatic stress disorder


Staphylococcal Scalded Skin Syndrome


Toxic epidermal necrolysis


  1. Auquier-Dunant A et al (2002) Severe cutaneous adverse reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138:1019–1024CrossRefGoogle Scholar
  2. Bastuji-Garin S et al (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149–153CrossRefGoogle Scholar
  3. Chen P et al (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364(12):1126–1133CrossRefGoogle Scholar
  4. Chung WH et al (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343–1350CrossRefGoogle Scholar
  5. Creamer D et al (2016) U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 174:1194–1227. https://www.has-sante.frCrossRefGoogle Scholar
  6. Dodiuk-Gad RP et al (2016) Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 175(2):422–424CrossRefGoogle Scholar
  7. Goldstein SM et al (1987) Toxic epidermal necrolysis. Unmuddying the waters. Arch Dermatol 123:1153–1156CrossRefGoogle Scholar
  8. Gonzalez-Herrada C et al (2017) Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol 137:2092–2100CrossRefGoogle Scholar
  9. Guillaume JC et al (1987) The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell’s syndrome). Arch Dermatol 123:1166–1170CrossRefGoogle Scholar
  10. Halevy S et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25–32CrossRefGoogle Scholar
  11. Kelly J et al (1995) An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 48:1099–1108CrossRefGoogle Scholar
  12. Lee HY et al (2017) Long term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis: the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multi-disciplinary follow up. Br J Dermatol 177(4):924–937CrossRefGoogle Scholar
  13. Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68:355–361CrossRefGoogle Scholar
  14. Mockenhaupt M et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:35–44CrossRefGoogle Scholar
  15. Olteanu C et al (2018) Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Saf 41(3):277–284. [Epub ahead of print]CrossRefPubMedGoogle Scholar
  16. Protocole National de Diagnostic et de Soins (PNDS) (2009) French recommendations for treatment of EN (in French). Available at
  17. Roujeau JC, Bastuji-Garin S (2011) Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf 2(3):87–94CrossRefGoogle Scholar
  18. Roujeau JC et al (1987) Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123:1171–1173CrossRefGoogle Scholar
  19. Roujeau JC et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333(24):1600–1607CrossRefGoogle Scholar
  20. Roujeau JC et al (2017) New evidence supporting cyclosporine efficacy in epidermal necrolysis. J Invest Dermatol 137:2047–2049CrossRefGoogle Scholar
  21. Sassolas B et al (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88(1):60–68CrossRefGoogle Scholar
  22. Sekula P et al (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133:1197–1204CrossRefGoogle Scholar
  23. Sotozono C et al (2015) Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 160:228–237CrossRefGoogle Scholar
  24. Stevens A, Johnson F (1922) A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Arch Pediatr Adolesc Med 24(6):526Google Scholar
  25. Wang CW et al (2018) Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 128(3):985–996CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jean-Claude Roujeau
    • 1
  1. 1.Université Paris-Est-CréteilCréteilFrance

Personalised recommendations